Building New Pharmaceutical Capabilities in Central Asia

在中亚建立新的制药能力

• 批准号: 6805115
• 负责人: ILYA RASKIN
• 金额: $ 79.12万
• 依托单位: RUTGERS, THE STATE UNIV OF N.J.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-26 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6805115
• 关键词: Asia; Commonwealth of Independent States; Fungi; biological products; cooperative study; drug discovery /isolation; drug screening /evaluation; international cooperation; medicinal plants; molecular biology information system; plant extracts; prokaryote

DESCRIPTION (provided by applicant): The Central Asia ICBG program will facilitate the development of the natural product-based pharmaceutical capabilities in Uzbekistan and Kyrgyzstan while encouraging biodiversity conservation and exploration, building research and economic capacity, developing ecologically-sustainable harvesting means and enhancing training and international cooperation. Uzbekistan and Kyrgyzstan possess diverse and largely unexplored biodiversity spread over a wide range of climatic zones. The program will integrate wide-ranging, state-of-the art, multiple-target screens performed by five separate groups with powerful structural and analytical approaches designed to characterize and develop therapeutic agents produced by plants, fungi and prokaryotes from Central Asia. The program will build upon a well-developed, longstanding cooperation between the scientists in the participating countries and Rutgers University, which is supported by comprehensive legal agreements. Human diseases relevant to this region will be purposely targeted, involvement of the local scientists actively encouraged and the ethnobiological knowledge upheld. Care will be taken to assure equitable benefit sharing and biodiversity treaties compliance. The screens associated with the proposed ICBG program will encompass 10 major therapeutic areas and close to 60 specific disease-related human targets and pathogenic microorganisms. The program will generate 108,000 prokaryotic, 10,260 plant and 6,000 fungal samples for the primary phase of these screens. A comprehensive training and bioinformatics initiative, made possible through major matching funds from Rutgers University and University of Illinois, will strengthen the research and development component of the program and further increase its impact on biodiversity preservation and inventory.

描述（由申请人提供）：中亚 ICBG 计划将促进乌兹别克斯坦和吉尔吉斯斯坦基于天然产物的制药能力的发展，同时鼓励生物多样性保护和探索、建设研究和经济能力、开发生态可持续的收获手段以及加强培训和国际合作。乌兹别克斯坦和吉尔吉斯斯坦拥有多样化且很大程度上未经开发的生物多样性，分布在广泛的气候带上。该计划将整合由五个不同小组进行的广泛、最先进的多目标筛选，以及强大的结构和分析方法，旨在表征和开发中亚植物、真菌和原核生物产生的治疗剂。该计划将建立在参与国科学家与罗格斯大学之间良好、长期的合作基础上，并得到全面法律协议的支持。将有目的地针对与该地区相关的人类疾病，积极鼓励当地科学家的参与并维护民族生物学知识。将注意确保公平的惠益分享和生物多样性条约的遵守。与拟议的 ICBG 项目相关的筛选将涵盖 10 个主要治疗领域和近 60 个与疾病相关的特定人类靶标和病原微生物。该计划将为这些筛选的第一阶段生成 108,000 个原核样本、10,260 个植物样本和 6,000 个真菌样本。通过罗格斯大学和伊利诺伊大学的主要配套资金，一项全面的培训和生物信息学举措成为可能，该举措将加强该计划的研究和开发部分，并进一步增加其对生物多样性保护和清单的影响。